Reports Q2 revenue $136.8M, consensus $127.15M. “Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescribers,” said Jeff Tangney, co-founder and CEO of Doximity (DOCS). “We’re proud to help physicians save time, so they can provide better care for their patients.”
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Big banks, UnitedHealth report quarterly earnings: Morning Buzz
- Etsy, Enphase downgraded: Wall Street’s top analyst calls
- Barclays upgrades Doximity to Overweight on advertising opportunity
- Doximity upgraded to Overweight from Equal Weight at Barclays
- Doximity price target raised to $45 from $34 at Evercore ISI